Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia.

IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Martine Paquette, Mark Trinder, Isabelle Ruel, Simon-Pierre Guay, Robert A Hegele, Jacques Genest, Liam R Brunham, Alexis Baass
{"title":"Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia.","authors":"Martine Paquette, Mark Trinder, Isabelle Ruel, Simon-Pierre Guay, Robert A Hegele, Jacques Genest, Liam R Brunham, Alexis Baass","doi":"10.1016/j.jacl.2025.01.004","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients with familial hypercholesterolemia (FH) are at increased risk of atherosclerotic cardiovascular disease (ASCVD). However, this risk is heterogeneous, and the contribution of several clinical risk factors has been well demonstrated in this population. The proportion of the risk conferred by the accumulation of common small effect variants in coronary artery disease (CAD) susceptibility genes remains to be determined.</p><p><strong>Objective: </strong>The objective was to determine if a weighted polygenic risk score (PRS) for CAD (PRS<sub>CAD</sub>) is associated with ASCVD risk in patients with heterozygous FH (HeFH).</p><p><strong>Methods: </strong>This study included 1886 participants with HeFH from 3 independent cohorts: the FH Canada national registry, the UK Biobank, and the Montreal Clinical Research Institute FH cohort. The lifelong ASCVD risk was compared between groups using Kaplan-Meier estimates and Cox proportional hazards regression models.</p><p><strong>Results: </strong>The group with a high PRS<sub>CAD</sub> (>75th percentile) had a ∼2-fold increased risk of ASCVD compared to those with a lower PRS<sub>CAD</sub> (≤75th percentile) (HR 1.92 (1.55-2.37), P < .0001). The effect of the PRS<sub>CAD</sub> on ASCVD risk remained significant after correction for clinical risk factors (P = .0002). This association was similar between women and men (P interaction = .68), between genetic and clinical FH (P interaction = .48), between cohorts (P interaction = .39), and between the type of PRS (P interaction = .81).</p><p><strong>Conclusion: </strong>We demonstrated in the largest study to date that the use of a PRS<sub>CAD</sub> allowed us to further refine risk stratification in HeFH. Further studies are needed to evaluate the clinical value of adding the PRS<sub>CAD</sub> to current risk prediction tools.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jacl.2025.01.004","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Patients with familial hypercholesterolemia (FH) are at increased risk of atherosclerotic cardiovascular disease (ASCVD). However, this risk is heterogeneous, and the contribution of several clinical risk factors has been well demonstrated in this population. The proportion of the risk conferred by the accumulation of common small effect variants in coronary artery disease (CAD) susceptibility genes remains to be determined.

Objective: The objective was to determine if a weighted polygenic risk score (PRS) for CAD (PRSCAD) is associated with ASCVD risk in patients with heterozygous FH (HeFH).

Methods: This study included 1886 participants with HeFH from 3 independent cohorts: the FH Canada national registry, the UK Biobank, and the Montreal Clinical Research Institute FH cohort. The lifelong ASCVD risk was compared between groups using Kaplan-Meier estimates and Cox proportional hazards regression models.

Results: The group with a high PRSCAD (>75th percentile) had a ∼2-fold increased risk of ASCVD compared to those with a lower PRSCAD (≤75th percentile) (HR 1.92 (1.55-2.37), P < .0001). The effect of the PRSCAD on ASCVD risk remained significant after correction for clinical risk factors (P = .0002). This association was similar between women and men (P interaction = .68), between genetic and clinical FH (P interaction = .48), between cohorts (P interaction = .39), and between the type of PRS (P interaction = .81).

Conclusion: We demonstrated in the largest study to date that the use of a PRSCAD allowed us to further refine risk stratification in HeFH. Further studies are needed to evaluate the clinical value of adding the PRSCAD to current risk prediction tools.

冠状动脉疾病多基因风险评分预测家族性高胆固醇血症患者的动脉粥样硬化性心血管疾病。
背景:家族性高胆固醇血症(FH)患者发生动脉粥样硬化性心血管疾病(ASCVD)的风险增加。然而,这种风险是异质性的,几个临床风险因素的贡献已经在这一人群中得到了很好的证明。冠状动脉疾病(CAD)易感基因中常见小效应变异积累所带来的风险比例仍有待确定。目的:目的是确定CAD (PRSCAD)的加权多基因风险评分(PRS)是否与杂合子FH (HeFH)患者的ASCVD风险相关。方法:本研究包括来自3个独立队列的1886名HeFH患者:FH加拿大国家登记处、英国生物银行和蒙特利尔临床研究所FH队列。使用Kaplan-Meier估计和Cox比例风险回归模型比较各组终生ASCVD风险。结果:与低PRSCAD组(≤75百分位)相比,高PRSCAD组(低于75百分位)发生ASCVD的风险增加了2倍(HR 1.92 (1.55-2.37), P < 0.0001)。在校正临床危险因素后,PRSCAD对ASCVD风险的影响仍然显著(P = 0.0002)。这种相关性在男女之间(P相互作用= 0.68)、在遗传和临床FH之间(P相互作用= 0.48)、在队列之间(P相互作用= 0.39)以及在PRS类型之间(P相互作用= 0.81)也相似。结论:我们在迄今为止最大规模的研究中证明,PRSCAD的使用使我们能够进一步完善HeFH的风险分层。需要进一步的研究来评估将PRSCAD添加到当前风险预测工具中的临床价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
6.80%
发文量
209
审稿时长
49 days
期刊介绍: Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. Sections of Journal of clinical lipidology will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信